Zedira Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Private

  • Employees
  • 18

Employees

  • Latest Deal Type
  • 2ndary - Private

Zedira General Information

Description

Developer of a transglutaminase inhibitor intended to generate homogenous antibody-drug conjugates. The company's biotechnological capabilities include drug discovery programs involving small molecules that block dysregulated transglutaminases and also services for the determination of microbial transglutaminase and research and development, enabling researchers to create specialty reagents and doctors to treat celiac disease patients.

Contact Information

Website
www.zedira.com
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • Roesslerstrasse 83
  • Hesse
  • 64293 Darmstadt
  • Germany
+49 06151
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Roesslerstrasse 83
  • Hesse
  • 64293 Darmstadt
  • Germany
+49 06151

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Zedira Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Secondary Transaction - Private 01-Nov-2023 Completed Generating Revenue
8. Grant 30-Nov-2016 Completed Clinical Trials - Phase 1
7. Grant 12-Feb-2015 Completed Clinical Trials - Phase 1
6. Grant 01-Jun-2011 Completed Clinical Trials - Phase 1
5. Early Stage VC 18-May-2010 Completed Startup
4. Grant 02-Jun-2009 Completed Startup
3. Early Stage VC (Series A) 01-Sep-2007 Completed Startup
2. Grant 04-Jul-2007 $3.36K Completed Startup
1. Accelerator/Incubator 01-Jan-2007 Completed Startup
To view Zedira’s complete valuation and funding history, request access »

Zedira Patents

Zedira Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024408031-A1 Oxo-pyridine derivatives as inhibitors of transglutaminases for use in the treatment of pulmonary fibrosis Pending 22-Dec-2023
EP-4637764-A1 Oxo-pyridine derivatives as inhibitors of transglutaminases for use in the treatment of pulmonary fibrosis Pending 22-Dec-2023
WO-2025133265-A1 Oxo-pyridine derivatives as inhibitors of transglutaminases for use in the treatment of pulmonary fibrosis Inactive 22-Dec-2023
WO-2023110138-A1 Inhibitors of transglutaminases Inactive 17-Dec-2021
US-20240270715-A1 Inhibitors of transglutaminases Pending 02-Jul-2021 C07D401/12
To view Zedira’s complete patent history, request access »

Zedira Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Zedira FAQs

  • When was Zedira founded?

    Zedira was founded in 2007.

  • Where is Zedira headquartered?

    Zedira is headquartered in Darmstadt, Germany.

  • What is the size of Zedira?

    Zedira has 18 total employees.

  • What industry is Zedira in?

    Zedira’s primary industry is Drug Discovery.

  • Is Zedira a private or public company?

    Zedira is a Private company.

  • What is Zedira’s current revenue?

    The current revenue for Zedira is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process